• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Ionis reports second quarter 2024 financial results

    8/1/24 7:00:00 AM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IONS alert in real time by email

    WAINUATM U.S. launch progressing well; approved in Canada; EU approval decision expected this year

    Olezarsen PDUFA December 19, 2024 for FCS

    Positive Phase 3 donidalorsen data for HAE; preparing U.S. and EU regulatory submissions

    On track to achieve 2024 financial guidance

    CARLSBAD, Calif., Aug. 1, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) (the "Company"), today reported financial results for the second quarter of 2024.

    Ionis logo (PRNewsfoto/Ionis Pharmaceuticals, Inc.)

    "Over the first half of this year, we continued to deliver on our goal to bring a steady cadence of medicines to people with serious diseases. The WAINUA launch for hereditary ATTR polyneuropathy (ATTRv-PN) continues to progress well with AstraZeneca. QALSODY is now approved in the EU, expanding the number of patients who can benefit from the first approved treatment for a genetic form of ALS. And we are well positioned for our first independent launch with olezarsen, which was accepted for Priority Review with a December FDA action date for people with familial chylomicronemia syndrome (FCS), a serious and rare disease with no approved treatments in the U.S. Additionally, we completed enrollment in our Phase 3 olezarsen program for the much larger severe hypertriglyceridemia (sHTG) patient population, keeping us on track for data in the second half of next year. And based on recent positive Phase 3 results, we believe donidalorsen, our second planned independent U.S. launch, is positioned to be a preferred choice for people with hereditary angioedema (HAE)," said Brett P. Monia, Ph.D., chief executive officer of Ionis. "We also advanced our next wave of potentially transformational medicines, including announcing plans to independently advance ION582 into a Phase 3 study next year, based on positive data in Angelman syndrome; this program is poised to become the cornerstone of our robust wholly owned neurology pipeline. Our recent achievements, together with multiple upcoming catalysts, position Ionis to deliver next-level value for all stakeholders."

    Second Quarter 2024 Summary Financial Results(1):





    Three months ended

    June 30,



    Six months ended

    June 30,





    2024



    2023



    2024



    2023





    (amounts in millions)

    Total revenue



    $225



    $188



    $345



    $319

    Operating expenses



    $291



    $279



    $560



    $523

    Operating expenses on a non-GAAP basis



    $260



    $252



    $498



    $469

    Loss from operations



    ($66)



    ($91)



    ($215)



    ($204)

    Loss from operations on a non-GAAP basis



    ($35)



    ($64)



    ($153)



    ($150)



















    (1)  Reconciliation of GAAP to non-GAAP basis contained later in this release.

     

    Financial Highlights

    • Revenue increased for the second quarter and first half of 2024 by 20% and 8% compared to the same periods last year, respectively, primarily driven by an increase in R&D revenue reflecting the value Ionis' pipeline and technology continues to generate
    • Operating expenses increased in the second quarter and first half of 2024 compared to the same periods last year, reflecting continued strategic investments in late-stage development, including WAINUA for ATTR cardiomyopathy and olezarsen for sHTG, and commercialization efforts for WAINUA, olezarsen and donidalorsen
    • Reaffirmed 2024 financial guidance

    Recent Marketed Medicines Highlights

    • WAINUA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN) generated sales of $16 million and $21 million resulting in royalty revenue of $4 million and $5 million in the second quarter and first half of 2024, respectively
    • WAINUA for the treatment of adults with ATTRv-PN approved in Canada
    • SPINRAZA for the treatment of spinal muscular atrophy (SMA) generated global sales of $429 million and $770 million resulting in royalty revenue of $57 million and $95 million in the second quarter and first half of 2024, respectively
    • QALSODY for the treatment of SOD1-ALS granted marketing approval in the EU

    Recent Late-Stage Pipeline Highlights

    • Olezarsen achieved multiple clinical and regulatory milestones that support pursuit of two patient populations with urgent unmet need, familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia (sHTG):
      • FDA accepted the NDA for patients with FCS for Priority Review with a PDUFA date of December 19, 2024
      • Presented positive Phase 3 Balance study data in patients with FCS with a simultaneous publication in the New England Journal of Medicine
      • Opened Expanded Access Program (EAP) for FCS in the U.S.
      • Completed enrollment for all Phase 3 sHTG studies: CORE pivotal study, CORE2 confirmatory pivotal study and ESSENCE supportive exposure study; on track for data across all three studies in H2:2025
      • Presented positive Phase 2b Bridge study data in patients with HTG and sHTG with a simultaneous publication in the New England Journal of Medicine
    • Donidalorsen achieved multiple clinical milestones positioning it to become the first RNA-targeted prophylactic treatment for people with hereditary angioedema (HAE):
      • Preparing to submit NDA
      • Otsuka preparing to submit MAA; expanded Otsuka EU commercial licensing agreement to include Asia Pacific
      • Presented positive Phase 3 OASIS-HAE study data in patients treated every four weeks or every eight weeks with a simultaneous publication in the New England Journal of Medicine
      • Presented positive Phase 3 OASISplus open-label extension study data in patients treated every four weeks or every eight weeks
      • Presented positive Phase 3 OASISplus switch study data in patients previously treated with other prophylactic therapies
    • Zilganersen (GFAP) Phase 3 study for the treatment of patients with Alexander disease fully enrolled; on track for data in 2025
    • Bepirovirsen Phase 3 studies for the treatment of patients with chronic hepatitis B (CHB) fully enrolled; on track for data in 2026

    Recent Other Pipeline Updates

    • Presented positive Phase 2 data for ION582 (UBE3A), our wholly owned medicine, in patients with Angelman syndrome; preparing for meetings with global regulators ahead of planned Phase 3 study start in H1:2025
    • Presented positive Phase 2 data for ION224 (DGAT2) in patients with metabolic dysfunction-associated steatohepatitis (MASH)
    • Initiated the Phase 1/2 Orbit study of ION356 (PLP1) in patients with Pelizaeus-Merzbacher disease (PMD)
    • Discontinued development of IONIS-FB-LRx for geographic atrophy (GA) and ION541 for amyotrophic lateral sclerosis (ALS) following completion of Phase 2 studies showing favorable safety profiles and good target engagement, but insufficient efficacy to advance into Phase 3 development

    Second Quarter 2024 Financial Results

    "Ionis is at a critical inflection point. We have achieved important development and regulatory milestones for WAINUA, olezarsen and donidalorsen, all of which have significant potential to help patients in need. In parallel, we continue to advance our next wave of potentially transformational medicines," said Elizabeth L. Hougen, chief financial officer of Ionis. "To drive next-level of value creation for all stakeholders, we remain focused on strategically investing our capital to fully unlock the potential of our promising near-and longer-term portfolio. Our investments are focused on go-to-market preparations for our upcoming planned olezarsen and donidalorsen launches. And with our increased confidence in the potential of WAINUA and olezarsen to address broader patient populations, we are planning additional investments to scale our capabilities in line with the significant potential that these important medicines represent. Additionally, we are investing in our next wave of medicines, including pre-commercialization activities and Phase 3 development for ION582 for Angelman syndrome, which we plan to start in the first half of next year. We expect our investments today and in the years ahead will position Ionis for sustainable growth for years to come."

    Revenue

    Ionis' revenue was comprised of the following:





    Three months ended



    Six months ended





    June 30,



    June 30,





    2024



    2023



    2024



    2023

    Revenue:



    (amounts in millions)

         Commercial revenue:

















    SPINRAZA royalties



    $57



    $61



    $95



    $111

    WAINUA royalties



    4



    -



    5



    -

    Other commercial revenue:

















    TEGSEDI and WAYLIVRA revenue, net



    8



    11



    17



    17

    Licensing and other royalty revenue



    3



    6



    15



    18

    Total commercial revenue



    72



    78



    132



    146

    Research and development revenue:

















    Amortization from upfront payments



    35



    15



    77



    29

    Milestone payments



    53



    51



    60



    74

    License fees



    38



    20



    38



    20

    Other services



    15



    4



    16



    6

    Collaborative agreement revenue



    141



    90



    191



    129

    WAINUA joint development revenue



    12



    20



    22



    44

    Total research and development revenue



    153



    110



    213



    173

    Total revenue



    $225



    $188



    $345



    $319

     

    Commercial revenue in the second quarter and first half of 2024 included a new source of royalty revenue with the launch of WAINUA in the U.S. in late January 2024. Ionis' commercial revenue in the second quarter and first half of 2024 also included royalties from the net sales of QALSODY, which Biogen launched in the U.S. in the second quarter of 2023 and in the EU in the second quarter of 2024.

    R&D revenue in the second quarter and first half of 2024 increased compared to the same periods last year primarily due to the amortization of upfront payments from the new collaborations with Roche and Novartis that Ionis entered into during the second half of last year. In addition, license fees increased year over year as a result of new collaborations Ionis entered into during the second quarter of 2024, including the expanded donidalorsen licensing agreement with Otsuka, which now includes the Asia-Pacific region in addition to Europe. These increases were partially offset by the decrease in WAINUA joint development revenue, which decreased as development activities relating to ATTRv-PN wound down with the launch of WAINUA for this indication.

    Operating Expenses

    Ionis' operating expenses increased in the second quarter and first half of 2024 compared to the same periods in 2023, consistent with expectations. SG&A expenses increased year over year primarily due to the launch of WAINUA in the U.S. and launch preparation activities for olezarsen and donidalorsen, including establishing the field team for olezarsen. R&D expenses decreased in the second quarter and were essentially flat in the first half of 2024 compared to the same periods last year as several late-stage studies have ended.

    Balance Sheet

    As of June 30, 2024, Ionis' cash, cash equivalents and short-term investments decreased to $2.1 billion compared to $2.3 billion at December 31, 2023. The Company plans to continue deploying its capital resources toward growth opportunities, and as previously guided, projects to end 2024 with $1.7 billion in cash, cash equivalents and short-term investments. Ionis' working capital also decreased over the same period primarily due to the Company's lower cash and short-term investments balance. We expect to make increased strategic investments in the years ahead, with a focus on late-stage programs, wholly owned assets, and our next wave of innovative medicines.

    Webcast

    Management will host a conference call and webcast to discuss Ionis' second quarter 2024 results at 11:30 a.m. Eastern time on Thursday, August 1, 2024. Interested parties may access the webcast here. A webcast replay will be available for a limited time at the same address. To access the Company's second quarter 2024 earnings slides click here.

    For more information about SPINRAZA and QALSODY, visit https://www.spinraza.com/ and https://www.qalsody.com/, respectively. QALSODY is approved under accelerated approval based on reduction in plasma neurofilament light chain (NfL) observed in patients treated with QALSODY. Continued approval may be contingent upon verification of clinical benefit in confirmatory trial(s).

    INDICATION for WAINUA™ (eplontersen)

    WAINUA injection, for subcutaneous use, 45 mg is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

    IMPORTANT SAFETY INFORMATION for WAINUA™ (eplontersen)

    WARNINGS AND PRECAUTIONS

    Reduced Serum Vitamin A Levels and Recommended Supplementation WAINUA leads to a decrease in serum vitamin A levels. Supplement with recommended daily allowance of vitamin A. Refer patient to an ophthalmologist if ocular symptoms suggestive of vitamin A deficiency occur.

    ADVERSE REACTIONS

    Most common adverse reactions (≥9% in WAINUA-treated patients) were vitamin A decreased (15%) and vomiting (9%).

    Please see link to U.S. Full Prescribing Information for WAINUA. 

    About Ionis Pharmaceuticals, Inc.

    For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has five marketed medicines and a leading pipeline in neurology, cardiology, and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter) and LinkedIn.

    Ionis' Forward-looking Statement

    This press release includes forward-looking statements regarding Ionis' business, financial guidance and the therapeutic and commercial potential of our commercial medicines, additional medicines in development and technologies. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties including those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. Except as required by law, we undertake no obligation to update any forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended December 31, 2023, and most recent Form 10-Q, which are on file with the Securities and Exchange Commission. Copies of these and other documents are available from the Company.

    In this press release, unless the context requires otherwise, "Ionis," "Company," "we," "our" and "us" all refer to Ionis Pharmaceuticals and its subsidiaries.

    Ionis Pharmaceuticals® is a registered trademark of Ionis Pharmaceuticals, Inc. Akcea Therapeutics® is a registered trademark of Akcea Therapeutics, Inc. TEGSEDI® is a registered trademark of Akcea Therapeutics, Inc. WAYLIVRA® is a registered trademark of Akcea Therapeutics, Inc. SPINRAZA® and QALSODY® are registered trademarks of Biogen. WAINUATM is a registered trademark of the AstraZeneca group of companies.

    Ionis Investor Contact:

    D. Wade Walke, Ph.D.

    [email protected]

    760-603-2331

    Ionis Media Contact:

    Hayley Soffer

    [email protected] 

    760-603-4679

     

    IONIS PHARMACEUTICALS, INC.

    SELECTED FINANCIAL INFORMATION

    Condensed Consolidated Statements of Operations

    (In Millions, Except Per Share Data)















    Three months ended



    Six months ended





    June 30,



    June 30,





    2024



    2023



    2024



    2023





    (unaudited)

    Revenue:

















         Commercial revenue:

















    SPINRAZA royalties



    $57



    $61



    $95



    $111

    WAINUA royalties



    4



    -



    5



    -

    Other commercial revenue



    11



    17



    32



    35

    Total commercial revenue



    72



    78



    132



    146

    Research and development revenue:

















    Collaborative agreement revenue



    141



    90



    191



    129

    WAINUA joint development revenue



    12



    20



    22



    44

    Total research and development revenue



    153



    110



    213



    173

    Total revenue



    225



    188



    345



    319

    Expenses:

















          Cost of sales



    4



    3



    6



    4

        Research, development and patent



    222



    230



    436



    428

        Selling, general and administrative



    65



    46



    118



    91

    Total operating expenses



    291



    279



    560



    523

    Loss from operations



    (66)



    (91)



    (215)



    (204)



















    Other income (expense):

















    Interest expense related to the sale of future royalties



    (18)



    (18)



    (36)



    (33)

    Other income, net



    18



    32



    42



    47

    Loss before income tax expense



    (66)



    (77)



    (209)



    (190)



















    Income tax expense



    -



    (8)



    -



    (20)



















    Net loss



    ($66)



    ($85)



    ($209)



    ($210)



















    Basic and diluted net loss per share



    ($0.45)



    ($0.60)



    ($1.43)



    ($1.47)

    Shares used in computing basic and diluted net loss per share



    146



    143



    146



    143

     

     

    IONIS PHARMACEUTICALS, INC.

    Reconciliation of GAAP to Non-GAAP Basis:

    Condensed Consolidated Operating Expenses, Loss From Operations, and Net Loss

    (In Millions)















    Three months ended

    June 30,



    Six months ended

    June 30,





    2024



    2023



    2024



    2023





    (unaudited)

    As reported research, development and patent

    expenses according to GAAP



    $222



    $230



    $436



    $428

        Excluding compensation expense related to equity awards      



    (23)



    (19)



    (45)



    (39)

    Non-GAAP research, development and patent

    expenses



    $199



    $211



    $391



    $389



















    As reported selling, general and administrative 

    expenses according to GAAP



    $65



    $46



    $118



    $91

        Excluding compensation expense related to equity awards      



    (8)



    (7)



    (17)



    (14)

    Non-GAAP selling, general and administrative

    expenses



    $57



    $39



    $101



    $77



















    As reported operating expenses according to GAAP



    $291



    $279



    $560



    $523

    Excluding compensation expense related to equity awards      



    (31)



    (27)



    (62)



    (54)

    Non-GAAP operating expenses



    $260



    $252



    $498



    $469



















    As reported loss from operations according to GAAP



    ($66)



    ($91)



    ($215)



    ($204)

        Excluding compensation expense related to equity awards      



    (31)



    (27)



    (62)



    (54)

    Non-GAAP loss from operations



    ($35)



    ($64)



    ($153)



    ($150)



















    As reported net loss according to GAAP



    ($66)



    ($85)



    ($209)



    ($210)

        Excluding compensation expense related to equity awards

          and related tax effects              



    (31)



    (27)



    (62)



    (54)

    Non-GAAP net loss



    ($35)



    ($58)



    ($147)



    ($156)

     

    Reconciliation of GAAP to Non-GAAP Basis

    As illustrated in the Selected Financial Information in this press release, non-GAAP operating expenses, non-GAAP loss from operations, and non-GAAP net loss were adjusted from GAAP to exclude compensation expense related to equity awards and the related tax effects. Compensation expense related to equity awards are non-cash. These measures are provided as supplementary information and are not a substitute for financial measures calculated in accordance with GAAP. Ionis reports these non-GAAP results to better enable financial statement users to assess and compare its historical performance and project its future operating results and cash flows. Further, the presentation of Ionis' non-GAAP results is consistent with how Ionis' management internally evaluates the performance of its operations.

    IONIS PHARMACEUTICALS, INC.

    Condensed Consolidated Balance Sheets

    (In Millions)

















    June 30,



    December 31,







    2024



    2023







    (unaudited)







    Assets:











      Cash, cash equivalents and short-term investments



    $2,079



    $2,331



      Contracts receivable



    27



    98



      Other current assets



    223



    213



      Property, plant and equipment, net



    76



    71



      Right-of-use assets



    167



    172



      Other assets



    119



    105



         Total assets



    $2,691



    $2,990















    Liabilities and stockholders' equity:











      Current portion of deferred contract revenue



    $94



    $151



      0.125% convertible senior notes, net – short-term



    44



    44



      Other current liabilities



    168



    253



      1.75% convertible senior notes, net



    564



    562

      0% convertible senior notes, net



    627



    625



      Liability related to sale of future royalties, net



    534



    514

      Long-term lease liabilities



    166



    171

      Long-term obligations, less current portion



    41



    42



      Long-term deferred contract revenue



    189



    241



      Total stockholders' equity



    264



    387



        Total liabilities and stockholders' equity



    $2,691



    $2,990



















     

    Key 2024 Value Driving Events(1) 

    New Product Launches

    Program

    Indication

    Achieved

    WAINUA

    ATTRv-PN

    • 

    Olezarsen

    FCS



    QALSODY (EU)

    SOD1-ALS

    • 



    Regulatory Actions

    Program

    Indication

    Regulatory Action

    Achieved

    Eplontersen

    ATTRv-PN

    Additional OUS filings

    •  

    EMA approval decision



    Additional OUS approval

    decision(s)

    • 

    Olezarsen

    FCS

    NDA filing

    • 

    FDA approval decision



    EU filing



    Canada filing



    Donidalorsen

    HAE

    NDA filing



    QALSODY

    SOD1-ALS

    EMA approval decision

    • 



    Key Phase 3 Clinical Data Events

    Program

    Indication

    Event

    Achieved

    Olezarsen

    FCS

    Balance study full data

     •  

    Donidalorsen

    HAE

    OASIS-HAE topline data

    • 

    Donidalorsen

    HAE

    OASIS-HAE full data

    • 

    Donidalorsen

    HAE

    OASIS-Plus: OLE + Switch

    data

    • 

    SPINRAZA

    SMA

    DEVOTE study data (high

    dose)





    Key Phase 2 Clinical Data Events

    Program

    Indication

    Event

    Achieved

    Donidalorsen

    HAE

    3-year Phase 2 OLE data



    IONIS-FB-LRx

    IgAN

    Phase 2 data



    IONIS-FB-LRx

    GA

    GOLDEN study data

    --

    ION224 (DGAT2)

    NASH

    Phase 2 data

     • 

    ION582 (UBE3A)

    Angelman syndrome

    HALOS study data

     • 

    ION541 (ATXN2)

    ALS

    ALSpire study data

    --

     

    (1)  Timing expectations based on current assumptions and subject to change.

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ionis-reports-second-quarter-2024-financial-results-302211668.html

    SOURCE Ionis Pharmaceuticals, Inc.

    Get the next $IONS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IONS

    DatePrice TargetRatingAnalyst
    4/7/2025$45.00Buy
    H.C. Wainwright
    3/31/2025$39.00Neutral
    Redburn Atlantic
    8/2/2024$67.00 → $60.00Outperform → Market Perform
    BMO Capital Markets
    7/24/2024$53.00 → $62.00Market Perform → Outperform
    Leerink Partners
    7/16/2024$29.00 → $75.00Buy
    Jefferies
    6/14/2024$44.00Underperform → Mkt Perform
    Bernstein
    4/10/2024$58.00Peer Perform → Outperform
    Wolfe Research
    1/2/2024$52.00 → $62.00Neutral → Buy
    BofA Securities
    More analyst ratings

    $IONS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Hayden Michael R bought $477,900 worth of shares (15,000 units at $31.86), increasing direct ownership by 43% to 50,219 units (SEC Form 4)

      4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)

      5/2/25 4:38:26 PM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, Corp and Development Ops Birchler Brian converted options into 1,875 shares and sold $19,292 worth of shares (680 units at $28.37), increasing direct ownership by 2% to 56,660 units (SEC Form 4)

      4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)

      4/17/25 4:53:27 PM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, Chf GL Pdt Str Ofcr Jenne Kyle sold $85,534 worth of shares (3,016 units at $28.36) and converted options into 12,226 shares, increasing direct ownership by 463% to 11,199 units (SEC Form 4)

      4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)

      4/17/25 4:53:18 PM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IONS
    SEC Filings

    See more
    • SEC Form 10-Q filed by Ionis Pharmaceuticals Inc.

      10-Q - IONIS PHARMACEUTICALS INC (0000874015) (Filer)

      4/30/25 3:56:17 PM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ionis Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - IONIS PHARMACEUTICALS INC (0000874015) (Filer)

      4/30/25 11:15:21 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Ionis Pharmaceuticals Inc.

      DEFA14A - IONIS PHARMACEUTICALS INC (0000874015) (Filer)

      4/25/25 4:26:13 PM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IONS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Ionis Pharma with a new price target

      H.C. Wainwright initiated coverage of Ionis Pharma with a rating of Buy and set a new price target of $45.00

      4/7/25 8:43:57 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Redburn Atlantic initiated coverage on Ionis Pharma with a new price target

      Redburn Atlantic initiated coverage of Ionis Pharma with a rating of Neutral and set a new price target of $39.00

      3/31/25 8:13:04 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ionis Pharma downgraded by BMO Capital Markets with a new price target

      BMO Capital Markets downgraded Ionis Pharma from Outperform to Market Perform and set a new price target of $60.00 from $67.00 previously

      8/2/24 7:32:04 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IONS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Ionis Pharmaceuticals Inc.

      SC 13G/A - IONIS PHARMACEUTICALS INC (0000874015) (Subject)

      11/14/24 8:34:57 PM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Ionis Pharmaceuticals Inc.

      SC 13G/A - IONIS PHARMACEUTICALS INC (0000874015) (Subject)

      11/14/24 1:28:29 PM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Ionis Pharmaceuticals Inc.

      SC 13G - IONIS PHARMACEUTICALS INC (0000874015) (Subject)

      11/8/24 10:52:38 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IONS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Hayden Michael R bought $477,900 worth of shares (15,000 units at $31.86), increasing direct ownership by 43% to 50,219 units (SEC Form 4)

      4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)

      5/2/25 4:38:26 PM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Hayden Michael R bought $181,079 worth of shares (5,000 units at $36.22), increasing direct ownership by 17% to 35,219 units (SEC Form 4)

      4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)

      12/26/24 4:57:52 PM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IONS
    Financials

    Live finance-specific insights

    See more

    $IONS
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $IONS
    Leadership Updates

    Live Leadership Updates

    See more
    • Ionis reports first quarter 2025 financial results

      - Encouraging start to first independent launch with TRYNGOLZATM - - On track for second independent launch with donidalorsen PDUFA August 21, 2025 - - Increasing 2025 financial guidance by more than 20% - Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) (the "Company") today reported financial results for the first quarter ended March 31, 2025. "With an encouraging start to the TRYNGOLZA launch for familial chylomicronemia syndrome, the first of four independent launches expected over the next two years, Ionis' new chapter as a fully integrated, commercial-stage biotechnology company is well underway," said Brett P. Monia, Ph.D., chief executive officer, Ionis. "We look forward to continued m

      4/30/25 7:00:00 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2024 Financial Results

      Up to four programs in registrational phase by 2025 Planned interim analysis for ulixacaltamide Essential3 Study 1 to be conducted in Q4 2024 Topline results for Phase 2 EMBOLD study of relutrigine (PRAX-562) in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) expected in Q3 2024 PRAX-628 Phase 2/3 POWER1 study to initiate in Q4 2024 Initiation of additional Phase 2 study (RADIANT) for PRAX-628 in focal and generalized epilepsy in 2H 2024, with topline results expected in 1H 2025 Cash and investments of $434 million as of June 30, 2024, maintains runway into 2027 BOSTON, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a

      8/13/24 7:00:00 AM ET
      $IONS
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ionis reports second quarter 2024 financial results

      WAINUATM U.S. launch progressing well; approved in Canada; EU approval decision expected this year Olezarsen PDUFA December 19, 2024 for FCS Positive Phase 3 donidalorsen data for HAE; preparing U.S. and EU regulatory submissions On track to achieve 2024 financial guidance CARLSBAD, Calif., Aug. 1, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) (the "Company"), today reported financial results for the second quarter of 2024. "Over the first half of this year, we continued to deliver on our goal to bring a steady cadence of medicines to people with serious dise

      8/1/24 7:00:00 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ionis to host 2025 virtual Annual Meeting of Stockholders

      Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that management will conduct its 2025 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 5, 2025. The agenda for the event is as follows: 5:00 p.m. – 5:15 p.m. ET (2:00 p.m. – 2:15 p.m. PT) – Virtual Annual Meeting of Stockholders All stockholders of record at the close of business on April 7, 2025, are invited to participate in the virtual Annual Meeting webcast, which will be broadcast live at www.virtualshareholdermeeting.com/IONS2025. Stockholders of record will receive an official proxy card from their brokerage firm. Each proxy card contains a 16-digit control number required

      5/6/25 7:05:00 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Praxis Precision Medicines Highlights DEE Clinical Program Updates at Virtual Investor Event

      BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, hosted a virtual investor event on its clinical programs in developmental and epileptic encephalopathies (DEEs) on Friday, May 2, 2025. "We were excited to highlight the significant opportunity in DEEs and progress Praxis is making in this field," said Marcio Souza, president and chief executive officer of Praxis. "Relutrigine continues to show tremendous promise to broadly address the DEE market

      5/5/25 8:00:00 AM ET
      $IONS
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ionis reports first quarter 2025 financial results

      - Encouraging start to first independent launch with TRYNGOLZATM - - On track for second independent launch with donidalorsen PDUFA August 21, 2025 - - Increasing 2025 financial guidance by more than 20% - Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) (the "Company") today reported financial results for the first quarter ended March 31, 2025. "With an encouraging start to the TRYNGOLZA launch for familial chylomicronemia syndrome, the first of four independent launches expected over the next two years, Ionis' new chapter as a fully integrated, commercial-stage biotechnology company is well underway," said Brett P. Monia, Ph.D., chief executive officer, Ionis. "We look forward to continued m

      4/30/25 7:00:00 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alltrna Announces Updates to Its Board of Directors

      Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera

      7/17/24 8:00:00 AM ET
      $APRE
      $CYTK
      $EVLO
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

      Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (NASDAQ:RNA), as an independent member of its Board of Directors. Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum's board. Ms. Boyce has extensive expertise in global pharmaceut

      6/24/24 4:05:00 PM ET
      $CTNM
      $IONS
      $NVS
      $RNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
      Medicinal Chemicals and Botanical Products
    • Ionis announces the appointment of Michael Yang to Board of Directors

      CARLSBAD, Calif., Dec. 14, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced the appointment of Michael Yang, an experienced biopharmaceutical executive, to the Ionis Board of Directors. Mr. Yang's appointment expands the total number of Ionis Board members to 10. Mr. Yang has more than 20 years of broad senior level leadership experience in biotech, pharmaceutical and medical device companies, where he launched new platforms, expanded global revenues and diversified product lines. He most recently served as President, Chief Executive Officer and B

      12/14/23 4:05:00 PM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care